Clover Health Investments (NASDAQ:CLOV) is positioning its Medicare Advantage model around earlier identification and treatment of chronic conditions, Interim Chief Financial Officer Clay Thornton said during a Canaccord Genuity conference presentation.
Thornton said the company’s goal is to equip physicians with artificial intelligence-powered technology that can identify, manage and treat chronic disease earlier. He said earlier intervention can support higher-quality care and more affordable, accessible care for Medicare Advantage members.
He said clinicians using the technology have been associated with lower hospitalizations and readmissions, while chronic kidney disease stage 3 diagnoses occurred 18 months earlier and diabetes treatment began 36 months earlier compared with cases where clinicians did not use the platform.
In-home care and member engagement
Thornton said Clover reaches approximately two-thirds of its members in a given year through at least one visit from a Clover Assistant-powered clinician. The company deploys the technology through its provider network and through Clover Care Services, which includes in-home assessments, readmission-prevention services and longitudinal primary care for members with more complex needs.
In Medicare, about 10% of members can account for roughly 60% of costs, Thornton said. Clover seeks to manage that higher-cost population through its in-home care program, with multiple clinician visits during the year. Enrollment in the program increased 84% relative to 2025, compared with roughly 50% membership growth across the company’s full book of business, he said.
The company retains full economic risk for its membership rather than delegating risk to providers, a model commonly used by other Medicare Advantage insurers. Thornton said Clover may be at an economic disadvantage during a member’s first two years but expects returns to improve as members remain enrolled longer and the company’s clinical interventions compound.
About 49% of Clover’s membership remains within the first two years of that lifecycle, including roughly 28% in their first year and 21% in their second year, he said. Thornton said the company expects cohort maturation to become more meaningful in 2027 and 2028 as newer members move into later years of enrollment.
New Jersey growth and retention
New Jersey remains Clover’s largest market. The company has doubled its overall membership over a two-year period, Thornton said, while its New Jersey market share increased to 31% from 20%. He said Clover had become the largest provider of non-special-needs Medicare Advantage plans in the state after surpassing United earlier this year.
Thornton said New Jersey offers both market-share and organic expansion opportunities, as Medicare Advantage penetration in the state is approximately 42%, compared with a national rate of a little more than 50%.
Clover’s network is 98% PPO, according to Thornton, allowing members to access lower-cost in-network benefits while also receiving care outside the network. He said the broader industry has increasingly shifted toward HMO products as a means of controlling costs, while Clover plans to remain “PPO first.”
The company retained more than 95% of members in the most recent annual enrollment period, Thornton said. He attributed retention in part to stable or improved benefits during a period when larger competitors have changed benefit offerings. He also said Clover has limited exposure to e-brokers, which he said can generate growth but may also contribute to weaker retention.
Profitability outlook and 2027 positioning
Thornton said Clover has grown membership at a 40% compound annual growth rate over the past two years, sustained adjusted EBITDA profitability and improved operating leverage by 500 basis points. For 2026, the company is guiding for its first full year of GAAP net income profitability alongside approximately 50% membership growth.
Rather than focusing primarily on medical loss ratio in a given year, Thornton said Clover monitors contribution profits by member cohort and consolidated gross profit per member per month. He said the company expects effective cohort progression to result in lower medical loss ratios over time.
Looking toward 2027, Thornton said Clover expects further disruption in the Medicare Advantage annual enrollment period as competitors respond to industry pressures. He said the company believes its product design and stable benefit approach position it to capitalize on member shopping activity.
On Star Ratings, Thornton said Clover’s 2027 bids were submitted at 4.5 stars. He said the company expects greater clarity on payment-year 2028 ratings in coming months as the federal plan-preview process advances. Thornton also said Counterpart Health, Clover’s separate business, continues to expand testing in new markets.
About Clover Health Investments (NASDAQ:CLOV)
Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.
At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.
